Indivior Pharmaceuticals, Inc. P/E Ratio 2022–2025
Indivior Pharmaceuticals, Inc. reported 21.88 of price-to-earnings ratio for fiscal 2025. That was 91.2% lower than fiscal 2024. Compared with fiscal 2024, the change was -91.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 21.88 | -91.2% |
| FY 2024 | 248.60 | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
Source: Indivior Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open INDV 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Indivior Pharmaceuticals, Inc. reported 21.88 of price-to-earnings ratio for fiscal 2025. That was 91.2% lower than fiscal 2024. Compared with fiscal 2024, the change was -91.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Indivior Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeIndivior Pharmaceuticals, Inc. — frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio?
Indivior Pharmaceuticals, Inc. (INDV) reported price-to-earnings ratio of 21.88 for fiscal year 2025, per its SEC filings.
How has Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2022 and 2025, INDV's price-to-earnings ratio declined at roughly 55.5% per year (compound annual rate), from 248.60 to 21.88.
Where does this data come from?
Figures are computed from Indivior Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More INDV financial history
Full INDV fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →